Moreover, early clinical trials have already shown promising results using GITR agonists to modulate the immunosuppressive tumor microenvironment when combined with conventional therapies or PD-1 inhibitors in patients with solid tumors, including glioblastoma [59–61]. This evidence concerns the gene TNFRSF18 and glioblastoma.